The FIGHT trial (Functional Impact of GLP-1 for HF Treatment) included 300 HFrEF patients with or without T2DM with a recent decompensation and were randomized to liraglutide or placebo for 6 months (86). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.